Lung Cancer

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.

Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.

FDA approves an updated Ibtrozi label for locally advanced or metastatic ROS1-positive NSCLC, reflecting nearly four years of response data.

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.

In the phase 3 ADAURA trial, 79% of patients who took Tagrisso for three years after lung cancer surgery were alive at eight years, compared with 64% of patients who received a placebo.

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.

Diagnosed with peritoneal mesothelioma at 21 and given 18 months to live, a survivor reflects on what turning 40 means nearly two decades later.

Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.

FDA grants accelerated approval to Hyrnuo (sevabertinib) for certain patients with HER2-mutated, advanced or metastatic non-small cell lung cancer.

T-cell engagers and other cellular therapies could help the immune system recognize and target lung cancer, including small cell lung cancer.

NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

Lung cancer patient and her father, a cancer survivor and caregiver, share how community, hope and self-advocacy helped them through treatment.

Tagrisso plus Orpathys improved progression-free survival in patients with EGFR-mutated lung cancer and MET overexpression, SANOVO trial shows.

Juanita Segura shares her nearly 12-year lung cancer journey, the power of community and why she advocates for biomarker testing and hope.

The phase 3 DESTINY-Lung04 trial met its main goal of keeping cancer from growing longer than chemotherapy plus immunotherapy did.

Lung cancer advocate Katie shares how losing her father to the disease and her own cancer journey inspire her work with LiveLung today.

At least half of patients get nervous before a follow-up scan. Dr. Geoffrey Pelz explains why that is common, what he wants patients to hear at the first visit and how much lung cancer treatment has shifted in 15 years.

An incidental CT scan revealed stage 1A lung cancer. After robotic surgery at Hackensack University Medical Center, Carolyn Rothfeld describes a recovery that took longer than she expected.

After receiving a stage 1 lung cancer diagnosis, Carolyn Rothfeld underwent robotic surgery to remove part of her lung and is back to her exercise routine nine months later.

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life.

Diagnosed with limited-stage small-cell lung cancer, Tammy shares how treatment progress and a mindset shift helped her find hope.

Heather Prather shares her stage 4 non small cell lung cancer journey, finding hope, joy and support through the LiveLung community and cancer advocacy.

Biomarker testing looks for genes, proteins and other markers in your cancer that can help your care team choose the most effective treatment for you.

As Canadian wildfire smoke blankets much of the U.S., here's what people with cancer and cancer survivors should know about the potential health risks.